BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Germ cell tumor AND GATA2, NFE1B, 2624, ENSG00000179348, MGC2306, P23769 AND Diagnosis
5 results:

  • 1. Overview of the 2022 WHO Classification of Pituitary Adenomas/Pituitary Neuroendocrine tumors: Clinical Practices, Controversies, and Perspectives.
    Wan XY; Chen J; Wang JW; Liu YC; Shu K; Lei T
    Curr Med Sci; 2022 Dec; 42(6):1111-1118. PubMed ID: 36544040
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. PATZ1 fusions define a novel molecularly distinct neuroepithelial tumor entity with a broad histological spectrum.
    Alhalabi KT; Stichel D; Sievers P; Peterziel H; Sommerkamp AC; Sturm D; Wittmann A; Sill M; Jäger N; Beck P; Pajtler KW; Snuderl M; Jour G; Delorenzo M; Martin AM; Levy A; Dalvi N; Hansford JR; Gottardo NG; Uro-Coste E; Maurage CA; Godfraind C; Vandenbos F; Pietsch T; Kramm C; Filippidou M; Kattamis A; Jones C; Øra I; Mikkelsen TS; Zapotocky M; Sumerauer D; Scheie D; McCabe M; Wesseling P; Tops BBJ; Kranendonk MEG; Karajannis MA; Bouvier N; Papaemmanuil E; Dohmen H; Acker T; von Hoff K; Schmid S; Miele E; Filipski K; Kitanovski L; Krskova L; Gojo J; Haberler C; Alvaro F; Ecker J; Selt F; Milde T; Witt O; Oehme I; Kool M; von Deimling A; Korshunov A; Pfister SM; Sahm F; Jones DTW
    Acta Neuropathol; 2021 Nov; 142(5):841-857. PubMed ID: 34417833
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Pituitary Gangliocytoma Producing TSH and TRH: A Review of "Gangliocytomas of the Sellar Region".
    Sakata K; Fujimori K; Komaki S; Furuta T; Sugita Y; Ashida K; Nomura M; Morioka M
    J Clin Endocrinol Metab; 2020 Oct; 105(10):3109-21. PubMed ID: 32706866
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. GATA3 immunoreactivity expands the transcription factor profile of pituitary neuroendocrine tumors.
    Mete O; Kefeli M; Çalışkan S; Asa SL
    Mod Pathol; 2019 Apr; 32(4):484-489. PubMed ID: 30390035
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Massively parallel sequencing reveals an accumulation of de novo mutations and an activating mutation of LPAR1 in a patient with metastatic neuroblastoma.
    Wei JS; Johansson P; Chen L; Song YK; Tolman C; Li S; Hurd L; Patidar R; Wen X; Badgett TC; Cheuk AT; Marshall JC; Steeg PS; Vaqué Díez JP; Yu Y; Gutkind JS; Khan J
    PLoS One; 2013; 8(10):e77731. PubMed ID: 24147068
    [TBL] [Abstract] [Full Text] [Related]  


    of 1.